(19)
(11) EP 4 370 133 A1

(12)

(43) Date of publication:
22.05.2024 Bulletin 2024/21

(21) Application number: 22753948.3

(22) Date of filing: 13.07.2022
(51) International Patent Classification (IPC): 
A61K 31/7088(2006.01)
C12N 15/113(2010.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/7088; C12N 15/1137; C12N 2310/11; C12N 2320/34; C12N 2320/30; A61P 19/00; A61P 21/00
(86) International application number:
PCT/US2022/073668
(87) International publication number:
WO 2023/288240 (19.01.2023 Gazette 2023/03)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 15.07.2021 US 202163222336 P
21.07.2021 US 202163224362 P

(71) Applicant: Vanda Pharmaceuticals Inc.
Washington, DC 20037 (US)

(72) Inventors:
  • PRZYCHODZEN, Bartlomiej
    Washington, Washington 20037 (US)
  • SMIESZEK, Sandra
    Washington, Washington 20037 (US)

(74) Representative: Appleyard Lees IP LLP 
15 Clare Road
Halifax HX1 2HY
Halifax HX1 2HY (GB)

   


(54) ANTISENSE OLIGONUCLEOTIDE (ASO) GENE INHIBITION AND TREATMENT